Public problems from the Supriya Lifescience active pharmaceutical material supplier witnessed strong demand from investors because of the subscription offer of 71.36 times.
It accepted an offer for 103.66 crore equity shares against the size of IPO 1.45 crore equity shares on December 20, the last day of the offer.
Inserted in March 2008, Supriya Life has a 38-focused niche product offering that focuses on various therapeutic segments such as antihistamines, analgesics, anesthesies, vitamins, anti-asthmatics and anti-allergic in October. This is the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride contributing to up to 45-50 percent and 60-65 percent, from fire exports from India, between FY17 and FY21.
Retail investors continue to provide strong support for their public problems because their portions are booked by subscribing 55.15 times. The portion of non-institutional investors was booked 161.22 times, while the section set aside for institutional investors who met the requirements saw 31.83 subscribing.
The global pharmaceutical market grew by around 5 percent of CAGR during CY14-CY20, and is expected to maintain this growth for the next 5 years to reach $ 1,585-1,625 billion in CY25 led by technological advancements, an increase in aging population and settled lifestyles.
Lifecience Supriya has a healthy balance sheet with a debt / equity ratio of 0.2x on H1FY22. The price band for offers, which opened on December 16, is Rs 265-274 per equity stock.
“On the price ribbon above RS 274, Supriya Life is available at a price / income of 16.7x (annual FY22E) which seems reasonably priced compared to his colleagues,” said Financial Services Geojit.
Brokers have set a “subscription” ranking for short terms with short term given its strong financial performance, including increasing margin, exposure exposure, capacity expansion and increased penetration to the regulated market.
The company plans to collect Rs 700 Crore through its public issues consisting of new editions of Rs 200 Crore and offers for sale of Rs 500 Crore. Fresh publishing money will be used for working capital needs and debt payments.
